A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
Status:
Completed
Trial end date:
2016-11-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the clinical efficacy, the patients quality of life, and safety of
oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate
plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the
Extension Phase of the trial.